Valuation Astellas Pharma Inc. OTC Markets

Stocks

ALPMY

US04623U1025

Pharmaceuticals

Market Closed - OTC Markets 01:29:59 22/08/2026 am IST			5-day change	1st Jan Change
15.04 ^USD	+0.53%		+3.44%	+13.17%

17/08	CLSA Starts Astellas Pharma at Accumulate with 3,000 Yen Price Target	MT
10/08	AbCellera's menopause drug cuts hot flashes in mid-stage trial, shares surge	RE

Company Valuation: Astellas Pharma Inc.

Data adjusted to current consolidation scope

Fiscal Period: March	2022	2023	2024	2025	2026	2027	2028	2029
Market Cap ¹	35,19,738	33,81,409	29,46,773	25,89,390	45,12,563	42,79,924	-	-
Change	-	-3.93%	-12.85%	-12.13%	74.27%	-5.16%	-	-
Enterprise Value (EV) ¹	32,03,752	30,04,569	26,11,086	32,32,444	47,96,910	42,38,050	38,40,850	34,82,571
Change	-	-6.22%	-13.1%	23.8%	48.4%	-11.65%	-9.37%	-9.33%
P/E	28.5x	34.7x	173x	51x	15.5x	11.6x	12.3x	15.8x
PBR	2.39x	2.24x	1.85x	1.71x	2.47x	2.11x	1.94x	1.85x
PEG	-	-1.8x	-2.1x	0x	0x	0.4x	-2.13x	-0.7x
Capitalization / Revenue	2.72x	2.23x	1.84x	1.35x	2.11x	1.85x	2x	2.26x
EV / Revenue	2.47x	1.98x	1.63x	1.69x	2.24x	1.83x	1.8x	1.84x
EV / EBITDA	13.6x	12.6x	14.2x	13.5x	8.31x	5.92x	5.8x	6.24x
EV / EBIT	20.6x	22.6x	102x	78.8x	12.5x	8.75x	8.5x	9.47x
EV / FCF	14.1x	10.3x	-3.88x	20.5x	9.72x	9.71x	7.45x	7.46x
FCF Yield	7.08%	9.7%	-25.8%	4.87%	10.3%	10.3%	13.4%	13.4%
Dividend per Share ²	50	60	70	74	78	80.29	82.86	85.15
Rate of return	2.62%	3.19%	4.26%	5.12%	3.1%	3.36%	3.47%	3.57%
EPS ²	67.08	54.24	9.51	28.35	162.8	205.9	194	150.9
Distribution rate	74.5%	111%	736%	261%	47.9%	39%	42.7%	56.4%
Net sales ¹	12,96,163	15,18,619	16,03,672	19,12,323	21,39,245	23,15,496	21,36,534	18,96,709
EBITDA ¹	2,35,370	2,38,767	1,83,358	2,40,171	5,77,227	7,16,076	6,62,456	5,58,086
EBIT ¹	1,55,686	1,33,029	25,518	41,039	3,82,633	4,84,244	4,52,097	3,67,633
Net income ¹	1,24,086	98,714	17,045	50,747	2,91,535	3,55,833	3,32,560	2,52,140
Net Debt ¹	-3,15,986	-3,76,840	-3,35,687	6,43,054	2,84,347	-41,873	-4,39,074	-7,97,352
Reference price ²	1,911.00	1,883.00	1,643.50	1,446.50	2,519.00	2,387.00	2,387.00	2,387.00
Nbr of stocks (in thousands)	18,41,831	17,95,756	17,92,986	17,90,107	17,91,411	17,93,014	-	-
Announcement Date	27/04/22	27/04/23	25/04/24	25/04/25	27/04/26	-	-	-

¹JPY in Million²JPY

Estimates

P/E, Detailed evolution

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (N)	EV / Sales (N)	EV / EBITDA (N)	Dividend Yield (N)	Capi.($)
ELI LILLY AND COMPANY	35.55x	12.84x	26.06x	0.55%	1,10900Cr
JOHNSON & JOHNSON	29.74x	-	-	2.01%	64TCr
ABBVIE INC.	33.42x	7.74x	16.11x	2.62%	46TCr
ROCHE HOLDING AG	20.72x	4.91x	12.16x	2.69%	37TCr
NOVARTIS AG	22.47x	5.78x	14.33x	2.76%	30TCr
ASTRAZENECA PLC	21.12x	4.35x	12.35x	2.02%	26TCr
AMGEN INC.	27.43x	7.09x	12.59x	2.33%	23TCr
NOVO NORDISK A/S	13.47x	4.79x	10.05x	3.81%	20TCr
GILEAD SCIENCES, INC.	-43.83x	6.34x	24.76x	2.3%	18TCr
Average	17.79x	6.73x	16.05x	2.34%	41.79TCr
Weighted average by Cap.	25.34x	8.43x	18.53x	1.91%